Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -14.45
- Piotroski Score 4.00
- Grade Buy
- Symbol (UBX)
- Company Unity Biotechnology, Inc.
- Price $1.41
- Changes Percentage (0.28%)
- Change -$0
- Day Low $1.40
- Day High $1.43
- Year High $2.60
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.67
- Trailing P/E Ratio -0.6
- Forward P/E Ratio -0.6
- P/E Growth -0.6
- Net Income $-39,860,000
Income Statement
Quarterly
Annual
Latest News of UBX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Is Unity Biotechnology (NASDAQ:UBX) In A Good Position To Invest In Growth?
Despite Unity Biotechnology's recent reduction in cash burn, shareholders should be cautious as the company's cash reserves may run out soon. With no revenue and high cash burn relative to market cap,...
By Yahoo! Finance | 2 months ago
